Circulating periostin levels do not differ between postmenopausal women with normal and low bone mass and are not affected by zoledronic acid treatment.

MLA

Anastasilakis, A. D., et al. “Circulating Periostin Levels Do Not Differ between Postmenopausal Women with Normal and Low Bone Mass and Are Not Affected by Zoledronic Acid Treatment.” Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones et Metabolisme, vol. 46, no. 2, Feb. 2014, pp. 145–49. EBSCOhost, https://doi.org/10.1055/s-0033-1351250.

APA

Anastasilakis, A. D., Polyzos, S. A., Makras, P., Savvides, M., Sakellariou, G. T., Gkiomisi, A., Papatheodorou, A., & Terpos, E. (2014). Circulating periostin levels do not differ between postmenopausal women with normal and low bone mass and are not affected by zoledronic acid treatment. Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones et Metabolisme, 46(2), 145–149. https://doi.org/10.1055/s-0033-1351250

Chicago

Anastasilakis, A D, S A Polyzos, P Makras, M Savvides, G T Sakellariou, A Gkiomisi, A Papatheodorou, and E Terpos. 2014. “Circulating Periostin Levels Do Not Differ between Postmenopausal Women with Normal and Low Bone Mass and Are Not Affected by Zoledronic Acid Treatment.” Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones et Metabolisme 46 (2): 145–49. doi:10.1055/s-0033-1351250.